Novartis receives FDA approval for Cosentyx® label update to include moderate to severe scalp psoriasis

February 7, 2018

Responsive image

EAST HANOVER, N.J., Feb. 8, 2018 /PRNewswire/ — Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Cosentyx® (secukinumab), the first interleukin-17A (IL-17A) antagonist approved to treat moderate to severe plaque psoriasis.1 The…

Category: Precious Metals